Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience

BACKGROUND: Human epidermal growth factor 2 (HER2)-low breast cancer, which is defined as HER2 1+ or 2+ in immunohistochemistry without gene amplification, accounts for a considerable part of all breast cancers. However, it remains controversial whether HER2-low breast cancer is a distinct entity. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hangcheng, Han, Yiqun, Wu, Yun, Wang, Yan, Li, Qing, Zhang, Pin, Yuan, Peng, Luo, Yang, Fan, Ying, Chen, Shanshan, Cai, Ruigang, Li, Qiao, Ma, Fei, Xu, Binghe, Wang, Jiayu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245921/
https://www.ncbi.nlm.nih.gov/pubmed/35785207
http://dx.doi.org/10.3389/fonc.2022.906011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245921/
https://www.ncbi.nlm.nih.gov/pubmed/35785207
http://dx.doi.org/10.3389/fonc.2022.906011

Ejemplares similares